The company's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. It's unlikely the share price will rise significantly soon under these conditions.
Zhejiang Jolly Pharmaceutical Stock Forum
No comment yet